ID   H-EMC-SS
AC   CVCL_1238
SY   HEMCSS; HEMC-SS
DR   CLO; CLO_0003701
DR   CLO; CLO_0051381
DR   CLDB; cl1625
DR   CLDB; cl4965
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMD00005690
DR   BioSample; SAMN03472276
DR   cancercelllines; CVCL_1238
DR   Cell_Model_Passport; SIDM00535
DR   ChEMBL-Cells; CHEMBL3308736
DR   ChEMBL-Targets; CHEMBL1075451
DR   Cosmic; 907290
DR   Cosmic-CLP; 907290
DR   DepMap; ACH-001519
DR   ECACC; 94042258
DR   EGA; EGAS00001000978
DR   GDSC; 907290
DR   GEO; GSM827448
DR   GEO; GSM1669877
DR   IARC_TP53; 21353
DR   ICLC; HTL99016
DR   LINCS_LDP; LCL-1458
DR   PharmacoDB; HEMCSS_419_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1238
DR   PubChem_Cell_line; CVCL_1238
DR   RCB; RCB0508
DR   Wikidata; Q54871889
RX   CelloPub=CLPUB00044;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=34413129;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 17.3-42.8 hours (CelloPub=CLPUB00044).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.61%; Native American=0.67%; East Asian, North=77.11%; East Asian, South=20.07%; South Asian=0.1%; European, North=0.01%; European, South=1.42% (PubMed=30894373).
CC   Caution: Does not harbor a gene fusion involving EWSR1 which is a hallmark of extraskeletal myxoid chondrosarcoma (PubMed=34413129).
CC   Derived from site: In situ; Muscle; UBERON=UBERON_0001630.
ST   Source(s): Cosmic-CLP; DepMap; RCB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9 (RCB)
ST   D13S317: 9,13 (Cosmic-CLP; DepMap)
ST   D16S539: 9,13
ST   D18S51: 16,24
ST   D21S11: 30,32.2
ST   D3S1358: 15,16
ST   D5S818: 10,12
ST   D7S820: 8,11
ST   D8S1179: 14,17
ST   FGA: 21,22
ST   Penta D: 9,10
ST   Penta E: 10,14
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C27502; Extraskeletal myxoid chondrosarcoma
DI   ORDO; Orphanet_209916; Extraskeletal myxoid chondrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   CelloPub=CLPUB00044;
RA   Ooshima F.;
RT   "Establishment of a new cell line from human extraskeletal myxoid
RT   chondrosarcoma.";
RL   Dokkyo J. Med. Sci. 19:1-9(1992).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=34413129; DOI=10.1158/1535-7163.MCT-21-0089;
RA   Gartrell J., Mellado-Largarde M., Clay M.R., Bahrami A., Sahr N.A.,
RA   Sykes A., Blankenship K., Hoffmann L., Xie J., Cho H.P., Twarog N.,
RA   Connelly M., Yan K.-K., Yu J.-Y., Porter S.N., Pruett-Miller S.M.,
RA   Neale G., Tinkle C.L., Federico S.M., Stewart E.A., Shelat A.A.;
RT   "SLFN11 is widely expressed in pediatric sarcoma and induces variable
RT   sensitization to replicative stress caused by DNA-damaging agents.";
RL   Mol. Cancer Ther. 20:2151-2165(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//